Clinical TrialJul 6, 2026, 01:01 AM
Molecular Partners MP0712 Phase 1/2a Dosing Ongoing; Data Soon
AI Summary
Molecular Partners provided an update on its Radio-DARPin therapeutics pipeline. Dosing is ongoing for MP0712 in its Phase 1/2a study, with initial data expected in the coming months and comprehensive efficacy data in 2027. Additionally, compassionate care has been initiated for a 225Ac-loaded DLL3 Radio-DARPin (MP0714) in South Africa, showcasing the versatility of DARPins. The company also plans first-in-human imaging for MP0726 in H2 2026, along with a new target nomination in H2 2026 and two INDs in 2027.
Key Highlights
- MP0712 Phase 1/2a trial dosing is ongoing in first patients.
- Initial data for MP0712 anticipated within the coming months.
- Comprehensive efficacy data for MP0712 expected in 2027.
- Compassionate care initiated for 225Ac-loaded DLL3 Radio-DARPin (MP0714) in South Africa.
- First-in-human imaging for MP0726 (targeting MSLN) planned to start in H2 2026.
- New target nomination planned in H2 2026.
- Two INDs planned across the portfolio in 2027.
Price Impact
More from MOLN